Latest News

Opsona Therapeutics Limited raises an additional €3 million.

Opsona Therapeutics Limited raises an additional €3 million (US $4 million) from Omnes Capital in Series C extension, resulting in a total financing round of € 36 million (US $48.6 million) October 2nd, 2013, Dublin, Ireland. – Opsona Therapeutics Limited (Opsona), the innate immune drug development company and portfolio company of Seroba Kernel Life...


3D Helical Stent Twelve Month Data Released

Paris, France, 21 May 2013. 3D Helical Stent Twelve Month Data Suggest Correlation between Stented Vessel Curvature and Primary Patency. Data presented during the Trials and Innovations for Peripheral Interventions Session at EuroPCR 2013 show that a stent with unique three-dimensional helical geometry, BioMimics 3D™, developed by Veryan Medical Ltd. - a...


Opsona Therapeutics Ltd. initiates a Phase II Study with OPN-305.

May 7th, 2013, Dublin, Ireland – Seroba Kernel's investee company, Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat autoimmune and inflammatory diseases, today announced that it has initiated a phase II clinical trial in renal transplant patients at high risk of delayed graft function with its...


< back to home page